BNP Paribas Financial Markets
NVLN

BNP Paribas Financial Markets’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

BNP Paribas Financial Markets’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-232
Closed -$168 – 4590
2019
Q3 		$168 Hold
232
– – ﹤0.01% 4446
2019
Q2 		$181 Buy
232
+36
+18% +$40 ﹤0.01% 4459
2019
Q1 		$241 Hold
196
– – ﹤0.01% 4197
2018
Q4 		$165 Hold
196
– – ﹤0.01% 4125
2018
Q3 		$580 Hold
196
– – ﹤0.01% 4341
2018
Q2 		$721 Sell
196
-3,019
-94% -$12.1K ﹤0.01% 4309
2018
Q1 		$11.3K Sell
3,215
-1,208
-27% -$5.12K ﹤0.01% 4008
2017
Q4 		$13.8K Buy
4,423
+2,947
+200% +$14.2K ﹤0.01% 4003
2017
Q3 		$10.4K Sell
1,476
-109
-7% -$874 ﹤0.01% 3862
2017
Q2 		$14.6K Buy
+1,585
New +$15.3K ﹤0.01% 3826

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

BNP Paribas Financial Markets's NVLN Position: Q4 2019 in Review

BNP Paribas Financial Markets sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 232 shares — an estimated $168 sold.

BNP Paribas Financial Markets first reported a position in NVLN in Q2 2017 and held it in 10 quarters. The position peaked at $14.6K in Q2 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • BNP Paribas Financial Markets reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 232 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $168.
  • BNP Paribas Financial Markets first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 10 quarters.
  • BNP Paribas Financial Markets's Novelion Therapeutics Inc. Common Shares position peaked at $14.6K in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2019, filed 12 Feb 2020.